Electromed (ELMD) Small-Cap Growth Virtual Investor Conference summary

Company overview and market opportunity

• Focuses on airway clearance with a single product, SmartVest, using high-frequency chest wall oscillation (HFCWO).

• All products are manufactured in Minnesota; annual revenue is $53 million with a $139 million market cap.

• Serves the bronchiectasis market, which is underdiagnosed and underprescribed, with 824,000 diagnosed patients in the US but only 127,000 treated with HFCWO.

• Market opportunity estimated at $2.3 billion, with a 12% annual increase in diagnosis and 8% market growth.

• Penetration rate is 15%, leaving significant room for growth among 700,000 potential patients.

Product features and patient support

• SmartVest is the newest, most intuitive HFCWO device, designed for ease of use by elderly patients.

• Features a single-hose, lightweight vest with touchscreen controls, improving comfort and compliance.

• Product is reimbursed by CMS and most private insurers, with an average sale price of $10,000 per unit.

• Direct-to-patient model includes support through the reimbursement process and ongoing clinical follow-up.

• Clinical evidence shows 59% fewer hospitalizations and 75% reduction in ER visits for users.

Revenue streams and business model

• 95% of revenue comes from home care, 4% from hospitals, and 1% from international sales.

• Direct-to-patient approach eliminates the DME middleman, increasing margins and control over the patient experience.

• About 50% of revenue is from Medicare, with commercial payers following Medicare rates.

• Gross profit margin is in the mid-70% range, with potential for further improvement through scale and efficiency.

• No debt, consistently profitable, and self-funding growth and reinvestment.